



National Audit of Primary Breast Cancer NAoPri, Clinical Effectiveness Unit

Royal College of Surgeons of England 38-43 Lincoln's Inn Fields London WC2A 3PE

E: <u>BreastCancerAudits@rcseng.ac.uk</u> T: 020 7869 6610 X NAoPri_news

Key COSD data items for collection 2023/2024

Demographics	England – COSD V9/10
NHS NUMBER (for linkage of datasets)	CR0010 NHS NUMBER
AGE	CR0100 PERSON BIRTH DATE
GENDER	CR3170 PERSON STATED GENDER CODE
DEPRIVATION	CR0080 POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)
ETHNICITY	CR0150 ETHNIC CATEGORY
Patient fitness	
PERFORMANCE STATUS	CR0510 PERFORMANCE STATUS (ADULT)
ASA SCORE	CR6010 ASA SCORE
FITNESS ASSESSMENT	BR4500 FITNESS ASSESSMENT INDICATOR
	BR4510 FITNESS ASSESSMENT DATE
	BR4520 CLINICAL FRAILTY SCORE
	BR4530 ABBREVIATED MENTAL TEST SCORE
	BR4540 CARDIORESPIRATORY DISEASE
	BR4550 OTHER NON-BREAST LOCALLY
	ADVANCED/METASTATIC MALIGNANCY
	BR4560 DEMENTIA DIAGNOSIS
Process	
REFERRAL SOURCE	CR1600 SOURCE OF REFERRALS FOR OUTPATIENTS
CONTACT TIMINGS	CR0230 DATE FIRST SEEN
	CR1360 DATE FIRST SEEN (CANCER SPECIALIST)
TRIPLE DIAGNOSTIC ASSESSMENT	BR4400 TRIPLE DIAGNOSTIC ASSESSMENT
ACCESS TO SUPPORT – CLINICAL NURSE	CR2050 CLINICAL NURSE SPECIALIST INDICATION
SPECIALIST	CODE
Diagnosis details	
DATE OF DIAGNOSIS	CR2030 DATE OF DIAGNOSIS (CLINICALLY AGREED)
DIAGNOSIS CODE	CR0370 PRIMARY DIAGNOSIS (ICD)
LATERALITY	CR0380 TUMOUR LATERALITY
PRETREATMENT STAGE DETAILS	CR0520 T CATEGORY (FINAL PRE-TREATMENT)
	CR0540 N CATEGORY (FINAL PRE-TREATMENT)
	CR0560 M CATEGORY (FINAL PRE-TREATMENT)
	CR0580 TNM STAGE GROUPING (FINAL PRE-
	TREATMENT)
	CR3120 STAGE DATE (FINAL PRETREATMENT STAGE)
INTEGRATED STAGE DETAILS	CR0620 T CATEGORY (INTEGRATED STAGE)
	CR0630 N CATEGORY (INTEGRATED STAGE)
	CR0640 M CATEGORY (INTEGRATED STAGE)
	CR0610 TNM STAGE GROUPING (INTEGRATED)
	CR3130 STAGE DATE (INTEGRATED STAGE)
PATHOLOGY	
TUMOUR GRADE	pBR4160 NON-INVASIVE GRADE









National Audit of Primary Breast Cancer NAoPri, Clinical Effectiveness Unit

Royal College of Surgeons of England 38-43 Lincoln's Inn Fields London WC2A 3PE

E: <u>BreastCancerAudits@rcseng.ac.uk</u> T: 020 7869 6610 X NAoPri_news

	pCR0410 GRADE OF DIFFERENTIATION (AT
	DIAGNOSIS)
NODAL INVOVLEMENT	pCR0890 NUMBER OF NODES EXAMINED
	pCR0900 NUMBER OF NODES POSITIVE
TUMOUR SIZE	pBR4180 NON-INVASIVE TUMOUR SIZE
	pBR4190 WHOLE TUMOUR SIZE
PATHOLOGICAL STAGE DETAILS	pCR0910 T CATEGORY (PATHOLOGICAL)
	pCR0920 N CATEGORY (PATHOLOGICAL)
	pCR0930 M CATEGORY (PATHOLOGICAL)
	pCR0940 TNM STAGE GROUPING (PATHOLOGICAL)
	pCR1010 SAMPLE COLLECTION DATE
MOLECULAR MARKERS – ER	pBR4220 ER STATUS
	pBR4230 ER ALLRED SCORE
MOLECULAR MARKERS – PR	pBR4290 PR STATUS
	pBR4300 PR ALLRED SCORE
MOLECULAR MARKERS – HER2	pBR4280 HER2 STATUS
	pBR4310 HER2 ISH STATUS
Treatment	
CANCER CARE PLAN	CR0460 CANCER CARE PLAN INTENT
	CR0470 PLANNED CANCER TREATMENT TYPE
REASON FOR NO TREATMENT	CR0490 NO CANCER TREATMENT REASON
Outcomes	
DATE OF RECURRENCE	CR6500 DATE OF NON PRIMARY CANCER PATHWAY
	(CLINICALLY AGREED)
RECURRENCE DETAILS	CR6520 RECURRENCE OR METASTATIC TYPE
SITE OF METASTASES	CR1590 METASTATIC SITE

Please note, as of 1 January 2018, TNMv8 should be submitted.

